Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
wPCbTP and Switching to AC in HER2-positive Breast Cancer
NCT02789657Phase 2Completed
- Sponsor
- Brown University
- Start
- Nov 2016
- Primary completion
- Nov 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of Paclitaxel Micelles for Injection in HER2-positive breast cancer (4 arms), sponsored by Brown University. Primary endpoints: Pathologic Complete Response at 18 weeks and Number of Patients Who Develop Major Toxicities at 18 weeks. Started Nov 2016; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02789657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789657.